



(12) Translation of
European patent specification

(11) NO/EP 3345903 B1

NORWAY

(19) NO

(51) Int Cl.

<i>C07D 209/88 (2006.01)</i>	<i>A61K 31/506 (2006.01)</i>
<i>A61K 31/343 (2006.01)</i>	<i>A61K 31/5377 (2006.01)</i>
<i>A61K 31/381 (2006.01)</i>	<i>A61K 31/541 (2006.01)</i>
<i>A61K 31/403 (2006.01)</i>	<i>A61K 31/7056 (2006.01)</i>
<i>A61K 31/404 (2006.01)</i>	<i>A61P 25/24 (2006.01)</i>
<i>A61K 31/4178 (2006.01)</i>	<i>A61P 25/28 (2006.01)</i>
<i>A61K 31/4439 (2006.01)</i>	<i>A61P 35/00 (2006.01)</i>
<i>A61K 31/454 (2006.01)</i>	<i>A61P 35/02 (2006.01)</i>
<i>A61K 31/4545 (2006.01)</i>	<i>A61P 35/04 (2006.01)</i>
<i>A61K 31/496 (2006.01)</i>	<i>A61P 43/00 (2006.01)</i>

Norwegian Industrial Property Office

(21)	Translation Published	2020.02.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.10.09
(86)	European Application Nr.	18158255.2
(86)	European Filing Date	2010.06.09
(87)	The European Application's Publication Date	2018.07.11
(30)	Priority	2009.06.10, JP, 2009139691
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2975024, 2010.06.09
(73)	Proprietor	Chugai Seiyaku Kabushiki Kaisha, 5-1, Ukima 5-chome, Kita-kuTokyo 115-8543, Japan
(72)	Inventor	Kinoshita, Kazutomo, c/o Chugai Seiyaku Kabushiki Kaisha200 KajiwaraKamakura-shi, Kanagawa, 247-8530, Japan Asoh, Kohsuke, c/o Chugai Seiyaku Kabushiki Kaisha200 KajiwaraKamakura-shi, Kanagawa, 247-8530, Japan Furuichi, Noriyuki, c/o Chugai Seiyaku Kabushiki Kaisha200 KajiwaraKamakura-shi, Kanagawa, 247-8530, Japan Ito, Toshiya, c/o Chugai Seiyaku Kabushiki Kaisha200 KajiwaraKamakura-shi, Kanagawa, 247-8530, Japan Kawada, Hatsuo, c/o Chugai Seiyaku Kabushiki Kaisha200 KajiwaraKamakura-shi, Kanagawa, 247-8530, Japan Ishii, Nobuya, c/o Chugai Seiyaku Kabushiki Kaisha200 KajiwaraKamakura-shi, Kanagawa, 247-8530, Japan Sakamoto, Hiroshi, c/o Chugai Seiyaku Kabushiki Kaisha200 KajiwaraKamakura-shi, Kanagawa, 247-8530, Japan

Hong, WooSang, Sibumhoban vertium, 1471-2501,122, Dongtandaerosibeom-gil,Hwaseong-si,, Gyeonggi-do 18476, Sør-Korea
Park, MinJeong, DRC, Sungkyunkwan University,2066, Seobu-ro, Jangangu,Suwon-si,, Gyeonggi-do, 16419, Sør-Korea
Ono, Yoshiyuki, c/o Chugai Seiyaku Kabushiki Kaisha1-135 KomakadoGotenba-shi, Shizuoka, 412-8513, Japan
Kato, Yasuharu, c/o Chugai Seiyaku Kabushiki Kaisha1-135 KomakadoGotenba-shi, Shizuoka, 412-8513, Japan
Morikami, Kenji, c/o Chugai Seiyaku Kabushiki Kaisha1-135 KomakadoGotenba-shi, Shizuoka, 412-8513, Japan
Emura, Takashi, c/o Chugai Seiyaku Kabushiki Kaisha1-135 KomakadoGotenba-shi, Shizuoka, 412-8513, Japan
Oikawa, Nobuhiro, c/o Chugai Seiyaku Kabushiki Kaisha200 KajiwaraKamakura-shi, Kanagawa, 247-8530, Japan

(74) Agent or Attorney ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **TETRACYCLIC COMPOUNDS**

(56) References
Cited: WO-A1-00/69856

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse eller salt eller solvat derav, hvorved forbindelsen er valgt fra gruppen bestående av:

5 9-etyl-8-[4-(2-hydroksy-etyl-amino)-piperidin-1-yl]-6,6-dimetyl-11-okso-6,11-dihydro-5H-benzo[b]karbazol-3-karbonitril og
8-(4-amino-piperidin-1-yl)-9-etyl-6,6-dimetyl-11-okso-6,11-dihydro-5H-benzo[b]karbazol-3-karbonitril.

10 **2.** Medikament omfattende som aktiv ingrediens en forbindelse ifølge krav 1 eller et salt eller solvat derav.

3. Forbindelse eller et salt eller et solvat ifølge krav 1 for anvendelse som ALK-inhibitor.

15 **4.** Forbindelse eller et salt eller solvat ifølge krav 1 for anvendelse i profylakse eller behandling av kreft, kreftmetastaser eller depresjon eller kognitiv sviktlidelse.